Outcome Capital is seeking an exceptional candidate to join as a Vice President to help its growing Biotechnology practice. This person will be responsible for following the progress of public/private Biotechnology companies, managing the deal team assigned to both potential and current clients and be responsible for deal origination and collaborating with and guiding the analyst and associate staff. In addition to a background in the life sciences, the ideal candidate will have core competence in equity research and financial modeling, specifically in the Healthcare and Biotechnology sectors. The position is located in Boston.
Outcome Capital is a highly specialized life science advisory and investment banking firm, providing innovative growth companies with a value-added, market-aligned approach to merger & acquisition, partnering, corporate finance and strategic advisory. The firm uses its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and strategic markets and implementing the best path for success. Outcome Capital’s strength stems from its multi-disciplinary, industry-dedicated experts who draw from their wide range of scientific, operational, strategic, financial, and transactional expertise across the value chain, and broad industry relationships. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD level scientists and clinicians, MBAs and experienced commercialization experts, our team is driven to propel innovation from the bench to bedside.
Outcome is proud of its unique culture of intellectual agility and openness, data-driven perspectives, strategic thinking, and commitment to teamwork. We are devoted to providing unmatched advisory services to our clients and share an uncompromised dedication to the life sciences industry’s success.
Outcome Capital is an Equal Opportunity Employer committed to a diversified and inclusive workforce. To apply, please write to email@example.com
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]Read More
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse NewsletterDownload